ArticleCancer cell2024
Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy.
Registry-linked trialOpen access · bronzeAbstract read
In one paragraph
Article in Cancer cell, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02107963 (A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors), which is not on this map. Cited by 88 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
88citing papers in PubMed, 1 pooled it
22.1field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors
Who cites it
88 citing papers in PubMed, 1 synthesis or guideline pooled it, 96 citations in OpenAlex.
- GD2-targeted immunotherapy in pediatric bone sarcomas: a systematic review of emerging strategies and combination approaches.Frontiers in immunology · 2026Pooled it
- The evolution of cellular therapies in sarcoma: Breakthroughs, challenges, and future directions.Human vaccines & immunotherapeutics · 2026Review
- Osteosarcoma Across the Age Spectrum: Why Outcomes Diverge and Trials Must Adapt.Journal of clinical medicine · 2026Review
- Chimeric antigen receptor (CAR)-T cell therapy for solid tumors in pediatric patients: current breakthroughs, dilemmas, and strategies.Experimental hematology & oncology · 2026Review
- Genomic landscape and tumor immune microenvironment of osteosarcoma: Bridging mechanistic insights to precision therapeutics.Bone reports · 2026Review
- Pediatric sarcomas: challenges and opportunities.Genes & development · 2026Review
- Successful autologous T cell apheresis in pediatric patients with hematologic malignancies, solid tumors, and brain tumors.Cytotherapy · 2026Article
- Spectrum, pathobiology, mechanistic insights and diagnostic challenges of post-CAR T cell therapy lymphoproliferative disorders.Nature reviews. Clinical oncology · 2026Review
- Class I HDAC inhibition enhances the stem-like memory properties of CRISPR-engineered CAR T cells in neuroblastoma.Molecular therapy. Oncology · 2026Article
- CAR T cells for pediatric CNS tumors: Clinical experience and reverse translational opportunities.Molecular therapy. Oncology · 2026Review
- Association of baseline immune cell composition with CAR-T cell expansion and survival in Relapsed/Refractory large B-Cell lymphoma.Journal of translational medicine · 2026Article
- The Conflicting Role of Myeloid Cells in CAR T-Cell Therapy.Cancer research · 2026Review
- LRRC15-CAR T Cells for the Treatment of Osteosarcoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Arming oncolytic herpes simplex virus with CXCL-11, IL-12 and a single-chain antibody against PD-1 to enhance CAR-T cell therapy in pancreatic ductal adenocarcinoma.Cell death & disease · 2026Article
- Defining the Functional Role and Potential as an Immunotherapeutic Target of ALCAM in Neuroblastoma.Molecular cancer therapeutics · 2026Article
- The quintessential role for CAR T cell therapy in children, adolescents and young adults with cancer.Nature reviews. Clinical oncology · 2026Review
- CAR-T cell therapy for pediatric solid tumors: armored CAR-T cells and beyond.Cancer metastasis reviews · 2026Review
- <p>Tumor microenvironment in bone sarcomas: Implications for immunotherapy and emerging therapeutic vulnerabilities (Review)</p>.Oncology reports · 2026Review
- Targeting metabolic reprogramming to enhance adoptive immunotherapy: emerging mechanisms and translational perspectives.Journal of translational medicine · 2026Review
- CAR-T cell immunotherapy in rhabdomyosarcoma.Journal of translational medicine · 2026Review
28 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
44 authors at 8 institutions in 2 countries.
Sabina KaczanowskaPediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Tara MurtyCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
Ahmad AlimadadiLa Jolla Institute for Immunology, La Jolla, CA, USA; Immunology Center of Georgia, Augusta University, Augusta, GA, USA; Georgia Cancer Center, Medical College of Georgia at Augusta University, Augusta, GA, USA.
Cristina F ContrerasPediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA; Department of Oncology, University of Oxford, Oxford, UK.
Caroline DuaultStanford Human Immune Monitoring Center, Stanford University School of Medicine, Stanford, CA, USA.
Priyanka B SubrahmanyamStanford Human Immune Monitoring Center, Stanford University School of Medicine, Stanford, CA, USA.
Warren ReynoldsCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
Norma A GutierrezLa Jolla Institute for Immunology, La Jolla, CA, USA.
Reema BaskarDepartment of Pathology, Stanford University, Stanford, CA, USA.
Catherine J WuBroad Institute, Cambridge, MA, USA; Dana-Farber Cancer Institute, Boston, MA, USA.
Franziska MichorBroad Institute, Cambridge, MA, USA.
Jennifer AltreuterBroad Institute, Cambridge, MA, USA.
Yang LiuBroad Institute, Cambridge, MA, USA.
Aashna JhaveriBroad Institute, Cambridge, MA, USA.
Vandon DuongCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
Hima AnbunathanCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
Claire OngPediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Hua ZhangPediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Radim MoravecCancer Therapy Evaluation Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Joyce YuDana-Farber Cancer Institute, Boston, MA, USA.
Roshni BiswasDana-Farber Cancer Institute, Boston, MA, USA.
Stephen Van NostrandDana-Farber Cancer Institute, Boston, MA, USA.
James LindsayDana-Farber Cancer Institute, Boston, MA, USA.
Mina PichavantImmunology Center of Georgia, Augusta University, Augusta, GA, USA.
Elena SotilloCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
Donna BernsteinPediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Amanda CarbonellPediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Joanne DerdakPediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Jacquelyn Klicka-SkeelsPediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Julia E SegalPediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Eva DombiPediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Stephanie A HarmonArtificial Intelligence Resource, Molecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Baris TurkbeyArtificial Intelligence Resource, Molecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Bita SahafCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
Sean BendallGeorgia Cancer Center, Medical College of Georgia at Augusta University, Augusta, GA, USA.
Holden MaeckerImmunology Center of Georgia, Augusta University, Augusta, GA, USA.
Steven L HighfillCenter for Cellular Engineering, Department of Transfusion Medicine, National Institutes of Health Clinical Center, Bethesda, MD, USA.
David StroncekCenter for Cellular Engineering, Department of Transfusion Medicine, National Institutes of Health Clinical Center, Bethesda, MD, USA.
John GlodPediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Melinda MerchantPediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Catherine C HedrickLa Jolla Institute for Immunology, La Jolla, CA, USA; Immunology Center of Georgia, Augusta University, Augusta, GA, USA; Georgia Cancer Center, Medical College of Georgia at Augusta University, Augusta, GA, USA.
Crystal L MackallCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
Sneha RamakrishnaCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA. Electronic address: ramakrs@stanford.edu.
Rosandra N KaplanPediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. Electronic address: rosie.kaplan@nih.gov.
National Institutes of Health · USStanford University · USBroad Institute · USDana-Farber Cancer Institute · USLa Jolla Institute for Immunology · USAugusta University Health · USNational Institutes of Health Clinical Center · USAugusta University · US
Funding
Translational Oncology Research Program (Project-005)P30CA124435 · NCI · STANFORD UNIVERSITY · PI Vittorio Sebastiano · 2007 to 2026
$71.4MMEDICAL SCIENTIST TRAINING PROGRAMT32GM007365 · NIGMS · STANFORD UNIVERSITY · PI CHUA, KATRIN F · 1985 to 2021
$33.8MMOLECULAR &CELLULAR IMMUNOBIOLOGYT32AI007290 · NIAID · STANFORD UNIVERSITY · PI Sean Curtis Bendall, Olivia M Martinez · 1985 to 2026
$27.0MStanford Cancer Immune Monitoring and Analysis Center (CIMAC)U24CA224309 · NCI · STANFORD UNIVERSITY · PI Sean Curtis Bendall, Holden T. Maecker · 2017 to 2026
$19.9MCancer Immune Monitoring and Analysis CenterU24CA224331 · NCI · DANA-FARBER CANCER INST · PI FRANK S HODI, Catherine Ju-Ying Wu · 2017 to 2026
$18.4MBiomarkers and Therapeutic Targets in Tumor Microenvironment and MetastasisZIABC011334 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI KAPLAN, ROSANDRA NATASHA · 2010 to 2025
$10.8MTumor Microenvironment in Cancer ProgressionZIABC011332 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI KAPLAN, ROSANDRA NATASHA · 2010 to 2025
$10.8MCCR Artificial Intelligence ResourceZIHBC012032 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI TÜRKBEY, BARIS · 2021 to 2025
$10.1MCancer Immunologic Data Commons (CIDC) Supplement RequestU24CA224316 · NCI · DANA-FARBER CANCER INST · PI CERAMI, ETHAN, MICHOR, FRANZISKA · 2017 to 2022
$6.8MFunctions of Nonclassical Monocytes in the VasculatureR01CA202987 · NCI · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI HEDRICK, CATHERINE C · 2016 to 2020
$2.2MProtective Role of Nonclassical Monocytes in Immunotherapies for Solid CancersU01CA224766 · NCI · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI HEDRICK, CATHERINE C, KAPLAN, ROSANDRA · 2018 to 2021
$1.4MDefining Pre-treatment Correlates of Patient GD2 CAR T Cell Exhaustion and Memory Using Multi-Dimensional Immune ProfilingK08CA267057 · NCI · STANFORD UNIVERSITY · PI Sneha Ramakrishna · 2022 to 2026
$1.1MIntramural NIH HHS ZIA BC011332Intramural NIH HHS ZIA BC011334NCI NIH HHS F30 CA271797NCI NIH HHS K08 CA267057NCI NIH HHS P30 CA124435NCI NIH HHS R01 CA202987NCI NIH HHS U01 CA224766NCI NIH HHS U24 CA224309NCI NIH HHS U24 CA224316NCI NIH HHS U24 CA224331NIGMS NIH HHS T32 GM007365
Abstract
Chimeric antigen receptor T cells (CAR-Ts) have remarkable efficacy in liquid tumors, but limited responses in solid tumors. We conducted a Phase I trial (NCT02107963) of GD2 CAR-Ts (GD2-CAR.OX40.28.z.iC9), demonstrating feasibility and safety of administration in children and young adults with osteosarcoma and neuroblastoma. Since CAR-T efficacy requires adequate CAR-T expansion, patients were grouped into good or poor expanders across dose levels. Patient samples were evaluated by multi-dimensional proteomic, transcriptomic, and epigenetic analyses. T cell assessments identified naive T cells in pre-treatment apheresis associated with good expansion, and exhausted T cells in CAR-T products with poor expansion. Myeloid cell assessment identified CXCR3
Indexed as
NeuroblastomaReceptors, Chimeric AntigenCell- and Tissue-Based TherapyChildHumansImmunotherapy, AdoptiveProteomicsReceptors, Antigen, T-CellT-LymphocytesYoung AdultReceptors, Antigen, T-CellReceptors, Chimeric AntigencancerCAR-T cellschimeric antigen receptorcorrelative studiesimmune suppressionimmunotherapymonocytesmyeloid cellsosteosarcomapediatric oncologysolid tumor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT02107963ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.